PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal; Evan A. Stein; Robert Dufour; Traci Turner; Fernando Civeira; Lesley Burgess; Gisle Langslet; Russell Scott; Anders Olsson; David Sullivan; G. Kees Hovingh; Bertrand Cariou; Ioanna Gouni‐Berthold; Ransi Somaratne; Ian Bridges; Robert C. Scott; Scott M. Wasserman; Daniel Gaudet

doi:10.1016/s0140-6736(14)61399-4

Keywords

EvolocumabEzetimibeMedicinePlaceboPCSK9Familial hypercholesterolemiaCholesterolStatinAlirocumabInternal medicineClinical trialDosingLdl cholesterolGastroenterologyEndocrinologyLipoproteinLDL receptorPathology

Affiliated Institutions

Related Publications

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

Paul M. Ridker

Twenty-two years ago, the landmark 4S trial demonstrated that statin therapy could reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among second...

2016 European Heart Journal 255 citations

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

Peter H. Jones , John A. Farmer , Michael D. Cressman +12 more

Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...

1991 Clinical Cardiology 65 citations

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

M. H. Frick , Olli Elo , Kauko Haapa +16 more

In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels ...

1987 New England Journal of Medicine 3872 citations

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

S. Féasson

Throughout the usual LDL cholesterol range in Western populations, lower blood concentrations are associated with lower cardiovascular disease risk. In such populations, therefo...

2002 The Lancet 6959 citations

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

James Shepherd , Gerard J. Blauw , Michael Murphy +17 more

Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established. Ou...

2002 The Lancet 3358 citations

Publication Info

Year: 2014
Type: article
Volume: 385
Issue: 9965
Pages: 331-340
Citations: 730
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

730

OpenAlex

Cite This

APA Style

                            
                                
                                    Frederick J. Raal, 
                                
                                    Evan A. Stein, 
                                
                                    Robert Dufour
                                
                                et al.
                            
                            (2014). 
                            PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. 
                            The Lancet
                            , 385
                            (9965)
                            , 331-340.
                            https://doi.org/10.1016/s0140-6736(14)61399-4
                        

Identifiers

DOI: 10.1016/s0140-6736(14)61399-4